Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K (2000) The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39:122–132
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo county rheumatoid arthritis register. Arthritis Rheum 43:522–530
CAS PubMed Article Google Scholar
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients—frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo county rheumatoid arthritis register. Arthritis Rheum 43:2776–2784
CAS PubMed Article Google Scholar
Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH (2014) Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53:1759–1766
van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112
Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P (2017) Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore) 96:e6983
Shim JH, Stavre Z, Gravallese EM (2018) Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif Tissue Int 102:533–546
CAS PubMed Article Google Scholar
Schett G, Saag KG, Bijlsma JWJ (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69:1415–1419
CAS PubMed Article Google Scholar
McInnes IB, Schett G (2011) Mechanisms of disease the pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219
CAS PubMed Article Google Scholar
Hauser B, Harre U (2018) The role of autoantibodies in bone metabolism and bone loss. Calcif Tissue Int 102:522–532
CAS PubMed Article Google Scholar
Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Investig 122:1791–1802
CAS PubMed PubMed Central Article Google Scholar
Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH (2015) Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis 74:1631–1632
CAS PubMed Article Google Scholar
Tsukasaki M, Takayanagi H (2019) Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 19:626–642
CAS PubMed Article Google Scholar
Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699
CAS PubMed Article Google Scholar
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M, For the GLORIA Trial consortium (2022) Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis 81(7):925–936
Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145–154
CAS PubMed Article Google Scholar
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520
Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P (2014) A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 73:1027–1036
CAS PubMed Article Google Scholar
den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, Raterman H, van Schaardenburg D, van Dillen N, Dijkmans B, Lems W (2014) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 73:1071–1078
Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399
Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23:231–235
CAS PubMed Article Google Scholar
Rolvien T, Jandl NM, Sturznickel J, Beil FT, Kotter I, Oheim R, Lohse AW, Barvencik F, Amling M (2021) Clinical and radiological characterization of patients with immobilizing and progressive stress fractures in methotrexate osteopathy. Calcif Tissue Int 108:219–230
CAS PubMed Article Google Scholar
Robin F, Cadiou S, Albert JD, Bart G, Coiffier G, Guggenbuhl P (2021) Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int 32:225–232
CAS PubMed Article Google Scholar
Ragab AH, Frech RS, Vietti TJ (1970) Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 25:580–585
CAS PubMed Article Google Scholar
Ruffer N, Krusche M, Beil FT, Amling M, Kotter I, Rolvien T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a systematic review. Semin Arthritis Rheum 52:151952
CAS PubMed Article Google Scholar
May KP, West SG, McDermott MT, Huffer WE (1994) The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 37:201–206
CAS PubMed Article Google Scholar
Carbone L, Vasan S, Elam R, Gupta S, Tolaymat O, Crandall C, Wactawski-Wende J, Johnson KC (2020) The association of methotrexate, sulfasalazine, and hydroxychloroquine use with fracture in postmenopausal women with rheumatoid arthritis: findings from the women’s health initiative. JBMR Plus 4:e10393
CAS PubMed PubMed Central Article Google Scholar
Elkayam O, Paran D, Flusser G, Wigler I, Yaron M, Caspi D (2000) Insufficiency fractures in rheumatic patients: misdiagnosis and underlying characteristics. Clin Exp Rheumatol 18:369–374
Buehring B, Al-Azem N, Andreica I, Kiefer D, Kiltz U, Tsiami S, Baraliakos X, Braun J (2021) Prevalence and risk factors of insufficiency fractures of the foot and ankle joint in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 73:2378–2380
Tengstrand B, Hafstrom I (2002) Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 29:2299–2305
Jin C, Zhang P, Zhang M, Zhang X, Lv L, Liu H, Liu Y, Zhou Y (2017) Inhibition of SLC7A11 by sulfasalazine enhances osteogenic differentiation of mesenchymal stem cells by modulating BMP2/4 expression and suppresses bone loss in ovariectomized mice. J Bone Miner Res 32:508–521
CAS PubMed Article Google Scholar
de Steenwinkel F, Hokken-Koelega A, Hazes J, Dolhain RJ (2013) Does elevated disease activity or medication use influence the bone density of the prepubertal offspring in pregnant women with rheumatoid arthritis? Arthritis and rheumatism. Wiley-Blackwell, HOBOKEN, pp S172–S172
Both T, Zillikens MC, Hoorn EJ, Zietse R, van Laar JA, Dalm VA, van Duijn CM, Versnel MA, Maria NI, van Hagen PM, van Daele PL (2016) Bone mineral density in sjogren syndrome patients with and without distal renal tubular acidosis. Calcif Tissue Int 98:573–579
CAS PubMed PubMed Central Article Google Scholar
Both T, Zillikens MC, Schreuders-Koedam M, Vis M, Lam WK, Weel A, van Leeuwen J, van Hagen PM, van der Eerden BCJ, van Daele PLA (2018) Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol 233:1424–1433
CAS PubMed Article Google Scholar
Both T, van de Peppel HJ, Zillikens MC, Koedam M, van Leeuwen J, van Hagen PM, van Daele PLA, van der Eerden BCJ (2018) Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med 22:873–882
McInnes IB, Gravallese EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21:680–686
CAS PubMed PubMed Central Article Google Scholar
Herman S, Muller RB, Kronke G, Zwerina J, Redlich K, Hueber AJ, Gelse H, Neumann E, Muller-Ladner U, Schett G (2008) Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 58:3041–3050
留言 (0)